Volume 11 Issue 6
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(6): 711-718
Liu Jingyi, Sun Liying, Zhu Zhijun, et al. Diagnosis and treatment of posttransplant lymphoproliferative diseases in liver transplant recipients: a single-center experience[J]. ORGAN TRANSPLANTATION, 2020, 11(6): 711-718. doi: 10.3969/j.issn.1674-7445.2020.06.010
Citation: Liu Jingyi, Sun Liying, Zhu Zhijun, et al. Diagnosis and treatment of posttransplant lymphoproliferative diseases in liver transplant recipients: a single-center experience[J]. ORGAN TRANSPLANTATION, 2020, 11(6): 711-718. doi: 10.3969/j.issn.1674-7445.2020.06.010
shu

Diagnosis and treatment of posttransplant lymphoproliferative diseases in liver transplant recipients: a single-center experience

doi: 10.3969/j.issn.1674-7445.2020.06.010

  • Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Clinical Diagnosis, Treatment and Research Center of Pediatric Liver Transplantation of Capital Medical University, Beijing 100050, China

More Information
  • Corresponding author: Sun Liying, E-mail:sunxlx@outlook.com
  • Received Date: 2020-08-04
    Available Online: 2021-01-19
  • Publish Date: 2021-01-19
    Abstract
  •   Objective  To summarize the incidence, diagnosis and treatment experience of posttransplant lymphoproliferative diseases (PTLD) in the liver transplant recipients.  Methods  Clinical data of 734 liver transplant recipients were retrospectively analyzed. The incidence, clinical symptoms, laboratory and imaging data of PTLD in liver transplant recipients were collected. The pathological results and treatment methods of PTLD recipients were analyzed. The prognosis of PTLD recipients was evaluated.  Results  The incidence of PTLD in liver transplant recipients was 2.2% (16/734). The median time of onset after operation was 8(3, 46) months. The main clinical manifestations of PTLD were fever and lymph nodes enlargement. Some patients developed anemia, hepatosplenomegaly, abnormal liver function and digestive system symptoms, etc. Among 16 PTLD recipients, 1 case showed abnormal increase in blood concentration of tacrolimus, 6 cases of elevated transaminase levels, 14 cases of increased Epstein-Barr virus (EBV) DNA load and 5 cases of increased cytomegalovirus (CMV) DNA load. Positron emission tomography and computed tomography (PET/CT) showed hypermetabolism of 18F-flurodeoxyglucose in the enlarged lymph nodes of 13 recipients. CT scan of the neck and abdomen indicated multiple lymph node enlargement in the corresponding area of 2 recipients. Lymph nodes enlargement of 1 recipient showed on ultrasound only. All 16 PTLD recipients received pathological examination. In situ hybridization showed that EBV-encoded small RNA (EBER) was positive in 13 recipients. Reducing the immunosuppressant level was the basal treatment plan for PTLD recipients, and it can be combined with rituximab-targeted therapy and chemotherapy according to different pathological types of PTLD. Surgery and radiotherapy were used for enlarged lymph nodes. One recipient died of transplant liver failure due to PTLD treatment.  Conclusions  Administration of immunosuppressants after liver transplantation can increase the risk of PTLD. The incidence of PTLD is higher in pediatric liver transplant recipients than in adults. Early diagnosis and reasonable treatment can significantly improve the prognosis of PTLD recipients.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    DIERICKX D, HABERMANN TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6):549-562. DOI: 10.1056/NEJMra1702693.
    [2]
    SWERDLOW SH, CAMPO E, PILERI SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390. DOI: 10.1182/blood-2016-01-643569.
    [3]
    QIN T, GU XQ, JEONG SS, et al. Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: a single-center experience[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(1):3-11. DOI: 10.1016/j.hbpd.2019.12.005.
    [4]
    KEMPF C, TINGUELY M, RUSHING EJ. Posttransplant lymphoproliferative disorder of the central nervous system[J]. Pathobiology, 2013, 80(6):310-318. DOI:10. 1159/000347225.
    [5]
    SINGAVI AK, HARRINGTON AM, FENSKE TS. Posttransplant lymphoproliferative disorders[J]. Cancer Treat Res, 2015, 165:305-327. DOI:10.1007/978-3-319-13150- 4_13.
    [6]
    L'HUILLIER AG, DIPCHAND AI, NG VL, et al. Posttransplant lymphoproliferative disorder in pediatric patients: characteristics of disease in EBV-seropositive recipients[J]. Transplantation, 2019, 103(11):e369-e374. DOI: 10.1097/TP.0000000000002898.
    [7]
    HSU CT, CHANG MH, HO MC, et al. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan[J]. J Formos Med Assoc, 2019, 118(11):1537- 1545. DOI: 10.1016/j.jfma.2018.12.023.
    [8]
    SEO E, KIM J, OH SH, et al. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients[J]. Pediatr Transplant, 2020, 24(4):e13666. DOI: 10.1111/petr.13666.
    [9]
    NARKEWICZ MR, GREEN M, DUNN S, et al. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience[J]. Liver Transpl, 2013, 19(7):730-740. DOI: 10.1002/lt.23659.
    [10]
    ØSTENSEN AB, SANENGEN T, HOLTER E, et al. No effect of treatment with intravenous ganciclovir on Epstein-Barr virus viremia demonstrated after pediatric liver transplantation[J]. Pediatr Transplant, 2017, 21(6):e13010. DOI: 10.1111/petr.13010.
    [11]
    ALDABBAGH MA, GITMAN MR, KUMAR D, et al. The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review[J]. Am J Transplant, 2017, 17(3):770-781. DOI: 10.1111/ajt.14020.
    [12]
    ALLEN UD, PREIKSAITIS JK, AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J]. Am J Transplant, 2013, 13 (Suppl 4): 107-120. DOI: 10.1111/ajt.12104.
    [13]
    SILVA JT, FERNÁNDEZ-RUIZ M, AGUADO JM. Prevention and therapy of viral infections in patients with solid organ transplantation[J]. Enferm Infecc Microbiol Clin, 2020, DOI: 10.1016/j.eimc.2020.01.021[Epub ahead of print].
    [14]
    GEORGE TI, JENG M, BERQUIST W, et al. EpsteinBarr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: case report and review of the literature[J]. Pediatr Blood Cancer, 2005, 44(3):270-276. DOI:10.1002/ pbc.20231.
    [15]
    MUMTAZ K, FAISAL N, MARQUEZ M, et al. Posttransplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a singlecentre experience with >1 000 liver transplantations[J]. Can J Gastroenterol Hepatol, 2015, 29(8):417-422. DOI: 10.1155/2015/517359.
    [16]
    BISHNOI R, MINISH J, FRANKE AJ, et al. Singleinstitution retrospective analysis of prognostic factors influencing very late-onset post-transplant lymphoproliferative disorder[J]. Cureus, 2020, 12(2):e6912.DOI: 10.7759/cureus.6912.
    [17]
    PETERS AC, AKINWUMI MS, CERVERA C, et al. The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience[J]. Transplantation, 2018, 102(9):1553-1562. DOI:10.1097/ TP.0000000000002146.
    [18]
    ABSALON MJ, KHOURY RA, PHILLIPS CL. Posttransplant lymphoproliferative disorder after solid-organ transplant in children[J]. Semin Pediatr Surg, 2017, 26(4):257-266. DOI: 10.1053/j.sempedsurg.2017.07.002.
    [19]
    CAMACHO JC, MORENO CC, HARRI PA, et al. Posttransplantation lymphoproliferative disease: proposed imaging classification[J]. Radiographics, 2014, 34(7):2025- 2038. DOI: 10.1148/rg.347130130.
    [20]
    XU YF, YANG JG. Roles of F-18-fluoro-2-deoxy-glucose PET/computed tomography scans in the management of post-transplant lymphoproliferative disease in pediatric patient[J]. PET Clin, 2020, 15(3):309-319. DOI:10.1016/ j.cpet.2020.03.006.
    [21]
    EVENS AM, ROY R, STERRENBERG D, et al. Posttransplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy[J]. Curr Oncol Rep, 2010, 12(6):383-394. DOI:10.1007/s11912- 010-0132-1.
    [22]
    GROSS TG, ORJUELA MA, PERKINS SL, et al. Lowdose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a children's oncology group report[J]. Am J Transplant, 2012, 12(11):3069- 3075. DOI: 10.1111/j.1600-6143.2012.04206.x.
    [23]
    TRAPPE R, OERTEL S, LEBLOND V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012, 13(2):196-206. DOI: 10.1016/S1470-2045(11)70300-X.
    [24]
    IGNACAK E, SUŁOWICZ J, GIZA A, et al. Posttransplant lymphoproliferative disorder in a patient after kidney transplant, 5-year follow-up: a case report[J]. Transplant Proc, 2020, 52(8):2517-2519. DOI:10.1016/ j.transproceed.2020.02.083.
    [25]
    VAN BESIEN K, BACHIER-RODRIGUEZ L, SATLIN M, et al. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk[J]. Leuk Lymphoma, 2019, 60(7):1693-1696. DOI:10.1080/10428 194.2018.1543877.
    [26]
    ROSSIGNOL J, TERRIOU L, ROBU D, et al. Radioimmunotherapy ((90) y-ibritumomab tiuxetan) for posttransplant lymphoproliferative disorders after prior exposure to rituximab[J]. Am J Transplant, 2015, 15(7):1976-1981. DOI: 10.1111/ajt.13244.
    [27]
    CHIOU FK, BEATH SV, WILKIE GM, et al. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children[J]. Pediatr Transplant, 2018, 22(2). DOI: 10.1111/petr.13133.
    [28]
    BUNCHORNTAVAKUL C, REDDY KR. Epstein-Barr virus and cytomegalovirus infections of the liver[J]. Gastroenterol Clin North Am, 2020, 49(2):331-346. DOI: 10.1016/j.gtc.2020.01.008.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (474) PDF downloads(47) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return